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Genital Chlamydia trachomatis Infections Clear More 
Slowly in Men Than Women, but Are Less Likely to 
Become Established
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Background. Rigorous estimates for clearance rates of untreated chlamydia infections are important for understanding chla-
mydia epidemiology and designing control interventions, but were previously only available for women.
Methods. We used data from published studies of chlamydia-infected men who were retested at a later date without having 
received treatment. Our analysis allowed new infections to take one of 1, 2, or 3 courses, each clearing at a different rate. We deter-
mined which of these 3 models had the most empirical support.
Results. The best-fitting model had 2 courses of infection in men, as was previously found for women: “slow-clearing” and 
“fast-clearing.” Only 68% (57%–78%) (posterior median and 95% credible interval [CrI]) of incident infections in men were 
slow-clearing, vs 77% (69%–84%) in women. The slow clearance rate in men (based on 6 months’ follow-up) was 0.35 (.05–1.15) 
year-1 (posterior median and 95% CrI), corresponding to mean infection duration 2.84 (.87–18.79) years. This compares to 1.35 
(1.13–1.63) years in women.
Conclusions. Our estimated clearance rate is slower than previously assumed. Fewer infections become established in men than 
women but once established, they clear more slowly. This study provides an improved description of chlamydia’s natural history to 
inform public health decision making. We describe how further data collection could reduce uncertainty in estimates.
Keywords. chlamydia; natural history; sexually transmitted diseases; Bayesian inference; evidence synthesis.
 
Chlamydia is the most commonly diagnosed sexually transmit-
ted infection in many countries and can have serious sequelae, 
especially in women, including pelvic inflammatory disease 
leading to ectopic pregnancy and infertility [1]. Widespread 
testing has been recommended in countries including Australia, 
England, the Netherlands, Sweden, and the United States. 
However, there is uncertainty about the effectiveness of testing 
programs as control measures [2]. Although randomized con-
trolled trials have provided evidence that screening can reduce 
the incidence of pelvic inflammatory disease [3, 4], a recent trial 
of chlamydia screening in the Netherlands observed no reduc-
tion in chlamydia prevalence [5, 6]. In young people in England, 
prevalence was similar in 1999–2001 and 2010–2012 [7], despite 
the rollout of the National Chlamydia Screening Programme 
(NCSP) from 2003, with full implementation by 2008. A better 
understanding of all aspects of chlamydia’s natural history and 
epidemiology is required in order to plan and implement reliably 
effective control measures that interrupt transmission by finding 
and curing infections that would otherwise be untreated.
Mathematical modeling studies are increasingly common 
tools for understanding the epidemiology of sexually transmit-
ted infections and planning and evaluating public health inter-
ventions [8–14]. Results and conclusions from these models 
are highly sensitive to their underlying assumptions, including 
the numerical values used to describe infection natural his-
tory [15, 16]. In models of chlamydia transmission and con-
trol, an important parameter is the clearance rate of untreated 
infections [15]. The more slowly clearance occurs, the higher 
the prevalence of untreated infection, and the more effective a 
screening intervention is likely to be. Conversely, if untreated 
infection is typically short-lived then intensive, active case-find-
ing including partner notification will be required to shorten 
the duration sufficiently to have an impact on prevalence and 
transmission. The duration of untreated chlamydia is a difficult 
quantity to measure, as the standard of care is to treat individ-
uals in whom infection has been detected. Perhaps for this rea-
son, a wide range of durations have been assumed in modeling 
studies, ranging from 180 days to 2–3 years in men and women 
[17]. Many estimates currently used in mathematical models 
are based on short-term studies, cohorts where participants 
M A J O R  A R T I C L E
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of 
America. This is an Open Access article distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted 
reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
DOI: 10.1093/infdis/jix283
Received 14 December 2016; editorial decision 6 June 2017; accepted 8 June 2017; published 
online June 13, 2017.
Correspondence: J. Lewis, PhD, Department of Infectious Disease Epidemiology, Imperial College 
London, St Mary’s Campus, Norfolk Place, London W2 1PG, UK (joanna.lewis@imperial.ac.uk).
XX
XXXX D
ow
nloaded from
 https://academ
ic.oup.com
/jid/article-abstract/216/2/237/3867429 by U
niversity of Birm
ingham
 user on 07 D
ecem
ber 2018
238 • JID 2017:216 (15 July) • Lewis et al
were treated at the time of the first test for a concurrent infec-
tion, or even the natural history of other infections [17].
Some of the most informative data on the duration of 
untreated infection comes from studies in which diagnosed 
cases were retested at a later date, having received no treatment 
between the 2 tests. If the time between testing and retesting 
is known, then the proportion of cases who had recovered in 
the interval provides information on the recovery rate. A recent 
report showed how this type of evidence from multiple studies 
could be synthesized to estimate the rate of chlamydia clearance 
and mean duration of infection in women [18]. Here, we apply 
the same method to estimate the rate of chlamydia clearance 
in men.
METHODS
We used a mixture-of-exponentials model [18] for the duration 
of untreated chlamydia infection in men. The model allows for 
any new infection to take one of several courses, each with a 
different clearance rate. Each infection thus belongs to one cat-
egory, or “class.” Within each class, durations of infection are 
exponentially distributed with mean equal to the reciprocal of 
the clearance rate for that class. To determine the appropriate 
number of classes, we compared the fit to the data of models 
comprised of 1, 2, and 3 classes. We also investigated a model 
in which clearance rates had a continuous Gamma distribu-
tion, rather than falling into discrete classes. The model also 
recognizes different study types: clinic-based studies recruit 
individuals who present for testing, perhaps because symptoms 
have recently developed or because of contact with an infected 
person. They therefore represent recent exposures and incident 
infections. Screening studies recruit members of the general 
population, more representative of prevalent infections. The 
proportion of detected infections belonging to faster-clearing 
infection classes is lower in screening studies than in patients 
seeking care after exposure to infection because these short 
infections clear quickly and, thus, are less common in the pool 
of prevalent infections.
We used 3 published literature reviews to identify relevant 
studies in which chlamydia-infected men were retested at a 
later date, having received no treatment in the interim [19–
21]. We updated these searches to cover the period since the 
original review but found no further relevant evidence. The 
search strategy for these updates is provided online at https://
github.com/joanna-lewis/ct_clearance. The studies provide 
information on natural (rather than antibiotic-induced) chla-
mydia clearance. In some cases, this formed the placebo or 
no-treatment arm of a comparison between different drugs; 
in others, it represented the delay between collecting a sam-
ple and the patient returning for treatment. In 1 case, patients 
were diagnosed during an army medical examination, and 
treatment was not actively sought by, or offered to, the asymp-
tomatic patients.
Eight studies were included and 165 men were retested alto-
gether, at a total of 18 time points after the original diagnostic 
test. Six studies (13 time points) were clinic-based and 2 (5 time 
points) were screening studies. Five studies (11 time points) 
used culture diagnosis methods; 3 (7 time points) used nucleic 
acid amplification tests (NAATs). Six (12 time points) diag-
nosed infection using urethral swabs, and 2 (6 time points) used 
urine samples. The data are summarized in Table 1. Citations 
for the studies used are provided online with the search strategy.
The studies were of moderately good quality. Most were 
prospective follow-up of infected patients. While older stud-
ies were often randomized clinical trials with a placebo arm, 
in more recent studies the only patients who were not treated 
presumptively were those without indications or infection risk 
factors such as urethritis or an infected partner. Several studies 
had <100% follow-up, and patients with persistent symptoms 
may have been more likely to return, causing a bias toward 
slow clearance rates. Potential confounders, which would have 
opposing effects, are unreported treatment and reinfection in 
the interval between the first and second tests. However, both of 
these would be expected to be rare over the periods of observa-
tion; studies of chlamydia reinfection in heterosexual men after 
treatment have estimated rates of around 10% per year [22, 23]. 
These studies provide the best evidence available to inform esti-
mates of the clearance rate of untreated infection.
The data inform parameter estimates for the mixture-of-ex-
ponentials model in a Bayesian inference framework. We found 
that the inference algorithm performed well only for models of 
duration consisting of 1 or 2 classes and not for 3 or more, so 
we did not investigate models of 3 or more classes any further. 
The clearance rate of short-duration (fast-clearing) infections 
proved difficult to identify, and was therefore fixed. Sensitivity 
analysis showed that estimates of the other parameters are 
insensitive to this value. To assess goodness-of-fit, we compared 
models with different numbers of infection classes, and differ-
ent fixed values for the fast clearance rate, using the residual 
deviance and deviance information criterion (DIC) [24]. In a 
well-fitting model, the residual deviance is expected to approx-
imate the number of data points. The DIC adjusts deviance to 
allow for model complexity, and a lower DIC indicates a better 
fit. We used uninformative prior distributions for the propor-
tion of infections that are slow-clearing (Beta(1,1) distribution) 
and for the clearance rate of slow-clearing infection (Exp(0.001) 
distribution). As in the analysis for women [18], the prior dis-
tribution for the sensitivity of culture diagnosis methods was 
informed by analysis of samples from men and women who had 
previously tested positive by culture and were retested using 
culture and NAATs [25]. In a large study comparing the sen-
sitivity of culture to NAAT diagnosis methods using different 
sample types [26], there was no evidence of a difference in the 
sensitivity of culture methods between urethral and cervical 
samples (113/146 urethral vs 102/125 cervical samples culture 
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positive; χ2 ~ 10–30; P ≈ 1); nor was there a significant difference 
between urethral and male urine samples (113/146 urethral vs 
112/145 urine samples culture positive; χ2 = 0.492; P = .483).
Posterior probability distributions for the 2 parameters (the 
proportion of infections clearing slowly, and the slow clearance 
rate) were obtained by Markov chain Monte Carlo sampling 
using the Stan system, via the rstan package [27] in the R statisti-
cal environment [28]. We also reproduced the analysis in women 
[18], to compare the posterior parameter distributions for men 
and women. We used the samples from the posterior distribu-
tions in each sex to derive samples for the difference in param-
eter values, by taking samples in turn and subtracting one from 
the other. Full details of the mathematical and statistical models 
are given in the R and Stan code used, which can be downloaded 
from https://github.com/joanna-lewis/ct_clearance.
RESULTS
The best-fitting model has 2 classes of infection, fast- and 
slow-clearing. This 2-class model provided a better description 
of the data (DIC = 23.3) than a model with 1 infection class 
and 1 constant clearance rate (DIC = 59.0), or a model in which 
clearance rates had a Gamma distribution (DIC = 31.8). Figure 
1 shows a validation of the model, in which the crude clear-
ance rate estimated using each data point in Table 1 is plotted 
alongside predictions from the mixture-of-exponentials model. 
The good agreement between observations and predictions 
shows that our hypothesis of 2 clearance rates can explain the 
discrepancies between the crude clearance rates in Table 1.
The posterior mean for the proportion of infections in the 
slower-clearing category was 0.677, and the median was 0.677 
(95% credible interval [CrI], .573–.779). For fast-clearing infec-
tions, we found that a clearance rate of 49 year-1, corresponding to 
mean duration 7.45 days, gave the best fit to data (ie, minimized 
the DIC). The posterior mean residual deviance was relatively 
high (21.6, compared with 18, the number of data points). For 
slow-clearing infections, the rate of chlamydia clearance was 0.35 
(.05–1.15) year-1 (median, 95% CrI); these quantiles correspond to 
mean infection durations 2.84 (.87–18.7) years assuming that the 
slow clearance rate remains constant beyond the 6-month range of 
the data. The very wide upper bound on the mean duration (lower 
bound on clearance rate) is due to the scarcity of long-term data.
Figure 2A uses the sampled parameter values to predict the 
survival of an incident infection (time zero equals the time of 
infection) and a prevalent infection (time zero equals the time 
of sampling from the population). Our posterior parameter dis-
tributions imply that prevalent infections are overwhelmingly 
slow-clearing, so that the duration of a prevalent infection is 
close to the equivalent for a slow-clearing infection. Figure 2B 
Table 1. Data Sources for the Duration of Untreated Chlamydia Infection in Men
First Author, Publication Yeara
Study Design; Sample 
Type; Diagnosis Method Follow-up Period
Estimated Mean 
Follow-up, y
No. Tested at 
Follow-up
No. Clearing CT 
Infection
Crude Clearance 
Rate, Year-1, Mean 
(95% CI)
Handsfield, 1976 Clinic; Urethral; Culture 1 wk (0.019 y) 0.019 10 0 0 (0–19.4)
Prentice, 1976 Clinic; Urethral; Culture 7–21 d (0.019–0.057 y); mean, 
8.5 d (0.023 y)
0.023 13 4 16.0 (4.1–41.4)
Johannisson, 1979 Clinic; Urethral; Culture 1 wk (0.019 y) 0.019 17 3 10.2 (2.0–30.0)
2 wk (0.038 y) 0.038 27 13 17.3 (8.9–30.0)
3 wk (0.058 y) 0.058 6 3 12.0 (2.2–36.8)
4 wk (0.077 y) 0.077 2 2 NA (2.2–NA)
Paavonen, 1980 Clinic; Urethral; Culture 4 wk (0.077 y) 0.077 21 7 5.3 (2.0–11.0)
Joyner, 2002 Clinic; Urine; NAAT 2–7 d (0.005–0.019 y) 0.012 15 3 18.6 (3.7–54.6)
8–14 d (0.022–0.038 y) 0.030 9 2 8.4 (1.0–30.6)
15–21 d (0.041–0.057 y) 0.049 4 1 5.9 (.1–33.5)
22–42 d (0.060–0.115 y) 0.088 4 0 0 (0–10.5)
43–112 d (0.118–0.307 y) 0.190 4 1 1.5 (.0–8.6)
Geisler, 2008 Clinic; Urethral; NAAT 4–59 d (0.011–0.162 y)b 0.045 14 5 9.8 (3.0–23.2)
Stamm, 1986 Clinic-based screening; 
Urethral; Culture
1 wk (0.019 y) 0.019 5 1 11.7 (.3–66.3)
2 wk (0.038 y) 0.038 2 0 0 (0–48.5)
3 wk (0.058 y) 0.058 2 0 0 (0–31.8)
4 wk (0.077 y) 0.077 1 0 0 (0–47.9)
van den Brule, 2002 Screening; Urine; NAAT 6 mo (0.5 y) 0.500 9 1 0.2 (.0–1.3)
Crude clearance rate is calculated using the formula –ln(1 – θ) / t, where t is the mean follow-up time and θ is the proportion of men having cleared infection. NA appears in the column for 
crude clearance rate where all of the men had cleared infection. The estimate and lower bound of the 95% confidence interval for θ were therefore zero, and the corresponding clearance 
rates were infinite. Intuitively this corresponds to the fact that if all men clear infection before observation, then there is the possibility that clearance is immediate. Mean follow-up for each 
time point was estimated as described by Price et al [18].
Abbreviations: CI, confidence interval; CT, Chlamydia trachomatis; NA, not available; NAAT, nucleic acid amplification test.
aSee online information for full citation.
bFollow-up period for men and women combined.
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shows the sampled posterior distribution for the clearance rate 
of slow-clearing infections in men, with the corresponding dis-
tribution for women [18] for comparison. The distribution for 
men lies to the left of that for women, indicating that the clear-
ance rate in men is likely to be slower than in women. The poste-
rior for men is wider than that for women because of the shorter 
maximum follow-up, the smaller number of time points, and the 
smaller numbers of men than women tested at each time point.
Individual posterior samples for women were subtracted 
from individual samples for men to provide sampled distribu-
tions for the differences between the sexes in the proportion of 
incident infections clearing slowly, and the rate of slow clear-
ance. These samples for the differences are plotted in Figure 3. 
The probability that episodes of slow-clearing infection clear 
more quickly in women than in men was 86% (the proportion 
of samples falling on the left-hand side of the plot). The proba-
bility that incident infections are more likely to be slow-clear-
ing in women than in men was 98% (the proportion of samples 
in the lower part of the plot). There is strong evidence (84% of 
samples in the bottom-left quadrant) that infections are more 
likely to be slow-clearing in women and these slow-clearing 
infections persist longer in men.
DISCUSSION
Our analysis is the first rigorous synthesis of the data availa-
ble on the duration of untreated chlamydia infection in men. 
It indicates that incident chlamydia infections in men fall into 
fast- or slow-clearing classes, as has been reported for women 
[18]. It is often assumed that untreated infections clear at 1 con-
stant rate [17], which we have now shown is an oversimplifica-
tion for men as well as for women. Furthermore, we find that 
slow-clearing infections in men generally have a lower clear-
ance rate than in women, the opposite of what has usually been 
assumed [17], but that exposure in men is less likely to result 
in an established infection. In countries reporting chlamydia 
testing, men test less frequently than women and fewer male 
infections are identified. Prolonged untreated infection in men 
means that identifying and treating infected men is an import-
ant priority for reducing transmission. We recommend greater 
focus on partner notification, to identify those persistently 
infected men who would be unlikely to receive treatment other-
wise. Failure to treat men’s infections limits the effectiveness of 
testing in women because even when infected women are found 
and treated, they become reinfected from the undetected infec-
tion reservoir in men.
Crude clearance rate (year−1)
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Figure 1. Validation of the model, showing crude (data; open circles) and simulated (model; filled circles) clearance rate for each data point in Table 1. Error bars give the 
95% confidence interval for crude estimates, and the central 95% of simulations. For crude estimates, an arrow pointing right indicates that all men cleared the infection, so 
there is no upper bound or estimate for the crude clearance rate (see also the legend to Table 1). The first 6 studies (above the dashed line) were clinic-based, and the last 
2 (below the line) were screening studies. Within this grouping, studies are ordered by maximum duration of follow-up. Follow-up in years at each observation is indicated 
on the left-hand side.
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It should be noted that our use of the reciprocal of the slow 
clearance rate to estimate the mean duration of slow-clear-
ing infections depends on the assumption that the clearance 
rate remains constant beyond the 6-month follow-up avail-
able in the data. In the absence of other information this is a 
reasonable, parsimonious assumption, but one that should be 
tested in future analyses of longer-term studies. Although the 
analysis took into account the imperfect sensitivity of cul-
ture diagnosis methods, it did not account for the possibility 
that an initially positive NAAT test could have detected DNA 
from dead bacteria, rather than viable organism. However, we 
would not expect this effect to affect the estimated slow clear-
ance rate, and indeed sensitivity analysis (see online code at 
https://github.com/joanna-lewis/ct_clearance) shows that there 
is no substantial evidence of a difference in slow clearance rate 
between the culture-based and NAAT-based studies. We also 
repeated the analysis excluding each study in turn to investigate 
whether any study might be affecting the results unduly, but 
found that only the removal of the 6-month study had a marked 
impact on the posterior distribution for duration of infection. 
This impact was a result of the longer follow-up in this study, 
rather than any difference in the quality of the evidence.
Our estimated duration of untreated infection of 2.84 years in 
men suggests that the durations of up to 200 days that are com-
monly assumed in modeling studies [17] are much too short. 
Persistent infection in men is consistent with evidence from 
several other studies. The Chlamydia Screening Studies (ClaSS) 
found there was no reduction in chlamydial load in urine 
samples from infected men retested between 14 and 62 days 
after diagnosis (median, 23.5 days) [29]. Chlamydia has been 
detected in semen from sperm donors at multiple time points 
over the course of 2 years [30], although this could represent 
repeat infections. A couple study of 1690 asymptomatic women 
and their male sex partners in which the mean duration of sex-
ual partnership ranged from 2 months to >10 years observed 
that chlamydia was detected more often in men than women 
[31], which is consistent with the duration of asymptomatic 
infection being longer in men than women. Finally, there is also 
population-level evidence that untreated infection lasts longer 
in men than women. Prior to the NCSP in England, prevalence 
in men and women was similar [32]. Infected women made 
fewer contacts than infected men [32] and the transmission 
probability from women to men is probably no higher than 
from men to women [17], suggesting that incidence was lower 
in men. Lower incidence could only result in a similar preva-
lence if the duration of infection is correspondingly longer.
The finding that there are fast- and slow-clearing infections in 
men as well as women, and the quantitative differences between 
men and women, are consistent with what is known about the 
biology of C. trachomatis and the human immune response. An 
explanation for the higher proportion of fast-clearing infections 
in men may be that urination makes it more difficult for the bac-
terium to remain present for long enough to penetrate the mucin 
barrier lining the urethra, allowing cell attachment and infection. 
This would not be the case with the female cervical epithelium, 
which continues to be exposed to chlamydia elementary bodies 
from the male ejaculate present in the vaginal fluid. The longer 
duration of established (slow-clearing) infections in men than 
Figure 2. A, Simulated survival curves for incident and prevalent infections in 
men. Solid lines indicate the median of the simulated proportion persisting, shaded 
areas the central 50% (the interquartile range), and dashed lines the central 95%. 
Note that the time axis is time since infection for incident infections, and time 
since detection of infection for prevalent infections. B, Posterior distributions for 
the clearance rate of slow-clearing chlamydia infections in men (blue) and women 
(pink), based on follow-up of up to 6 months in men and 4 years in women.
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in women may be explained by differences in sex hormones, 
which affect the immune response. Estradiol mainly enhances 
the immune response whereas testosterone is generally immu-
nosuppressive [33]. This would be consistent with the observa-
tion that chlamydia antibodies are detected less often in men 
following infection than in women, although the precise role of 
antibody in resolving infection is unclear [34, 35] and human 
and animal studies suggest that the cellular immune response is 
also important for protection [36, 37].
Until the uncertainty in the clearance rate of chlamydia that 
we have quantified here has been reduced by further study, it is 
important that it should be recognized in statistical and modeling 
analyses [15, 16]. We need a better understanding of the duration 
of untreated chlamydia, and indeed of other sexually transmit-
ted bacterial infections: this duration is also poorly character-
ized for gonorrhea [38] and Mycoplasma genitalium [39, 40], and 
reliable estimates are important for informing decisions about 
whether to test for and treat this latter emerging infection. As 
infected individuals should be treated promptly, natural history 
cannot be followed directly but valuable additional information 
could come from more studies retesting infected individuals, 
for example when they return to healthcare for treatment after 
testing positive. Large-scale public health programs provide an 
ideal opportunity to do this in a prevalent population, and the 
very fast clearance rates of short infections (estimated as 49 year-
1 and 120 year-1 in men and women, respectively) mean that even 
as screening programs are extended, the majority of infections 
detected this way will still be prevalent rather than incident. 
England’s NCSP [41] monitors the delay between testing and 
treatment of infected patients, enabling patients with the longest 
delays, who would contribute most additional statistical infor-
mation to our estimates, to be selected for retesting. It would be 
important to obtain information from these patients on the rea-
son for the delay. For example, a patient who recovered and was 
then reinfected might have experienced the disappearance and 
then return of symptoms, prompting retesting. Linkage of patient 
records would allow studies examining whether the association 
between faster natural clearance of infection and lower rates of 
reinfection, reported by Geisler et  al [42] for mostly African 
American women in a sexually transmitted disease clinic setting, 
occurs in other populations. Additionally, as the gastrointestinal 
tract may be an important reservoir for chlamydia infection in 
women because of the possibility of autoinfection [43, 44], rectal 
testing could be used to obtain estimates of the duration of rectal 
infection. A strength of the Bayesian approach that we have used 
is that different types of information can be incorporated as they 
become available to improve estimates in the future. For exam-
ple, data from whole-genome sequence analysis could provide a 
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lower-bound estimate for the duration of infection by inform-
ing on the interval between acquisition of infection and onward 
transmission, as has been recently applied to gonorrhea [45].
We have provided new, statistically rigorous estimates for the 
duration of untreated chlamydia infection in men, synthesiz-
ing data from several studies. The estimates add to a growing 
understanding of chlamydia epidemiology [46] and natural 
history [1, 42], which is essential if we are to make improved 
public health decisions. Given the importance of knowing the 
duration of untreated infection for understanding the natu-
ral history of chlamydia and other infections, we recommend 
further study in both men and women, including extragenital 
infections. We recommend that large-scale screening programs 
retest individuals returning for treatment after testing positive, 
particularly those patients with long delays, who are the most 
informative cases. This needs to be considered urgently, before 
implementation of point-of-care testing closes the gap between 
testing and treatment, removing this opportunity to deepen our 
understanding and improve public health.
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